sustained viral response hematological markers during the treatment of chronic hepatitis c infection in children

Sustained Viral Response Hematological Markers During The Treatment of Chronic Hepatitis C Infection in Children

We read with interest the paper by Pawlowska et al. (1) and we would like to add some comments. They conducted a retrospective cohort study of children with chronic hepatitis C (CHC) infection who completed treatment with ribavirin (RBV) plus pegylated IFN (peg-IFN) or recombinant IFN, and concluded that a mild decrease in hemoglobin levels , leukocyte and platelet counts during treatment may b...

sustained viral response and hematological adverse events during chronic hepatitis c infection treatment

Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment

Hepatitis C virus (HCV), as a causative agent of chronic liver disease, has infected approximately 175 million people (almost 3%) of the world's population; and 3 to 4 million new cases are added to this figure annually (1). Chronic HCV infection may progress to severe outcomes in the form of cirrhosis and hepatocellular carcinoma (HCC) (2). Currently, there is no effective HCV vaccine on the h...

hematological adverse events and sustained viral response in children undergoing therapy for chronic hepatitis c infection

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

BACKGROUND Treatment of hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin (RBV) is associated with adverse events, which may affect the patient's adherence to the treatment regimen and the treatment efficacy. OBJECTIVES The aim of this study was to assess the sustained viral response (SVR) and interdependence between the haematological characteristics (leukocyte count, pla...

sustained viral response and hematological adverse events in children with chronic hepatitis c